Next generation dengue vaccines: a review of candidates in preclinical development (Q37904025)

25 August 2017

1 reference

title

Next generation dengue vaccines: a review of candidates in preclinical development (English)

1 reference

25 August 2017

0 references

2

John Roehrig

1 reference

25 August 2017

3

Alan Barrett

1 reference

25 August 2017

4

Joachim Hombach

1 reference

25 August 2017

Julia Schmitz

1

1 reference

PubMed ID

21781998

25 August 2017

language of work or name

English

0 references

publication date

21 July 2011

1 reference

25 August 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

25 August 2017

29

1 reference

25 August 2017

7276-7284

1 reference

25 August 2017

42

1 reference

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Cost of dengue cases in eight countries in the Americas and Asia: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Economic impact of dengue illness in the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue vaccine candidates in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue vaccines: state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immune response to dengue virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Neutralization and antibody-dependent enhancement of dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Antibodies determine virulence in dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Antibody-mediated neutralization of flaviviruses: a reductionist view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Structural proteomics of dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Antigenic structure of flavivirus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Cross-reacting antibodies enhance dengue virus infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immature Dengue Virus: A Veiled Pathogen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Report of an NIAID workshop on dengue animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A mouse model for studying dengue virus pathogenesis and immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Humanized mice show clinical signs of dengue fever according to infecting virus genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Rationalizing the development of live attenuated virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Live attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue vaccine prospects: a step forward

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Unmet needs in modern vaccinology: adjuvants to improve the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

The coming of age of virus-like particle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Use of viral vectors for the development of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

TLR9 signaling in B cells determines class switch recombination to IgG2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

New mouse model for dengue virus vaccine testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.017

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.07.017

1 reference

25 August 2017

1 reference

PubMed ID

21781998